
Karuna Therapeutics announced the acceptance of its New Drug Application (NDA) for KarXT (xanomeline-trospium) by the U.S. Food and Drug Administration (FDA). The application, targeting schizophrenia treatment in adults, is set for a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. Positive trial results show improved symptoms without common antipsychotic side effects. KarXT addresses a crucial need for innovative treatments for severe mental illnesses like schizophrenia.
Like
Save
Share